Dermata Therapeutics, Inc.

DRMA Nasdaq SEC CIK 1853816
Follow Dermata Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $74.1K
Net income −$2.8M −66.8% vs same quarter last year
EPS, diluted −$0.55 +66.7% vs same quarter last year
Operating cash flow −$2.6M −46.9% vs same quarter last year
Net income by quarter
−$3.2M
−$2.3M
−$1.7M
−$1.7M
−$1.9M
−$1.8M
−$3M
−$2.8M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
−$15M−$10M−$5M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$7.6M
FY24−$12.3M
FY23−$7.8M
FY22−$9.6M
FY21−$7.9M
FY20−$3.2M
FY19-